



IFW

I hereby certify under oath this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 25, 2004.

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

INFORMATION DISCLOSURE
STATEMENT
Examining Group 3731
Patent Application
Docket No. UF-336XC3D1
Serial No. 10/812,776

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 3731
Applicant : David F. Muir
Serial No. : 10/812,776
Filed : March 29, 2004
Conf. No. : 4996
For : Materials and Methods for Nerve Grafting, Selection of Nerve Grafts, and In Vitro Nerve Tissue Culture

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.97 and §1.98, the applicant would like to bring to the attention of the Examiner, the references cited in the following patent application:

U.S. Serial No. 10/218,864, filed August 13, 2002.

The subject application, Serial No. 10/812,776, claims the benefit under 35 USC §120 of the filing date of patent application Serial No. 10/218,864. The applicant respectfully requests that the copies of references supplied in the Information Disclosure Statements of the 10/218,864 application, as well as references cited during the prosecution thereof, be made of record in the 10/812,776 application. As copies of the references filed in the 10/218,864 application, and cited on the attached

form PTO/SB/08, can be found in the 10/218,864 casework, copies of those references are not provided herewith.

Please note that DE 19530556 (citation no. F9) is in a foreign language. In accordance with MPEP §609, an English language abstract of DE 19530556 and a foreign Examination Report citing DE 19530556 were submitted in the 10/218,864 application (citation nos. F10 and R56, respectively, on the attached form PTO/SB/08).

It is respectfully requested that the references cited in the 10/218,864 application be considered in the examination of the subject application and that their consideration be made of record.

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.


Respectfully submitted,



Glenn P. Ladwig
Patent Attorney
Registration No. 46,853
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

GPL/mv

Attachment: Form PTO/SB/08 (7 pages)



Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/812,776
(use as many sheets as necessary)				Filing Date	March 29, 2004
Sheet	1	of	7	First Named Inventor	David F. Muir
				Group Art Unit	3731
				Examiner Name	
				Attorney Docket Number	UF-336XC3D1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
U1	2003/0068815	A1		Stone et al.	04-10-2003	All
U2	2001/0039459	A1		Stone	11-08-2001	All
U3	2001/0034043	A1		Su et al.	10-25-2001	All
U4	6,455,309	B2		Stone	09-24-2002	All
U5	6,267,786	B1		Stone	07-31-2001	All
U6	6,231,608	B1		Stone	05-15-2001	All
U7	6,093,563			Bennett et al.	07-25-2000	All
U8	6,054,569			Bennett et al.	04-25-2000	All
U9	5,997,863			Zimmermann et al.	12-07-1999	All
U10	5,916,557			Berlowitz-Tarrant et al.	06-29-1999	All
U11	5,716,617			Khandke et al.	02-10-1998	All
U12	5,292,509			Hageman	03-08-1994	All
U13	5,231,580			Cheung et al.	07-27-1993	All
U14	4,933,185			Wheatley et al.	06-12-1990	All
U15	4,696,816			Brown	09-29-1987	All
U16	10/218,316			Muir (patent application)	08-13-2002	All
U17	10/218,315			Muir (patent application)	08-13-2002	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴			
						T ⁶
F1	WO	91/06573	A1	La Jolla Cancer Res. Foundation	05-16-1991	All
F2	WO	91/06303	A1	Case Western Reserve Univ.	05-16-1991	All
F3	WO	01/39795	A2	IBEX Tech., Inc.	06-07-2001	All
F4	WO	01/35977	A2	IBEX Tech., Inc.	05-25-2001	All
F5	EP	0 875 253	A2	Seikagaku Corp.	11-04-1998	All
F6	EP	0 613 949	A2	Maruha Corporation	09-07-1994	All
F7	EP	0 776 968	A1	Sumitomo Bakelite Co.	06-04-1997	All

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	2	of	7	Application Number	10/812,776
				Filing Date	March 29, 2004
				First Named Inventor	David F. Muir
				Group Art Unit	3731
				Examiner Name	
				Attorney Docket Number	UF-336XC3D1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
U18		6,200,564	B1	Lamont et al.	03-13-2001	All
U19		6,214,978	B1	Truog et al.	04-10-2001	All
U20		5,866,120		Karageozian et al.	02-02-1999	All
U21		5,830,468		Bini	11-03-1998	All
U22						
U23						
U24						
U25						
U26						
U27						
U28						
U29						
U30						
U31						
U32						
U33						
U34						

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
F8	EP	0 576 294		A2	Seikagaku Kogyo Kabushiki Kaisha	12-29-1993	All	
F9	DE	19530556			Minuth Will Prof Dr	09-05-1996	All	
F10	DE	19530556	(English abstract)		Minuth Will Prof Dr	09-05-1996	All	
F11								
F12								
F13								
F14								

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JUN 29 2004

PTO/SB/08B (08-00)

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

7

Application Number	10/812,776
Filing Date	March 29, 2004
First Named Inventor	David F. Muir
Group Art Unit	3731
Examiner Name	

Attorney Docket Number UF-336XC3D1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AGIUS, E. and P. COCHARD "Comparison of Neurite Outgrowth Induced by Intact and Injured Sciatic Nerves: A Confocal and Functional Analysis" <i>The Journal of Neuroscience</i> , January 1, 1998, 18(1):328-338.	
	R2	BENNETT, G.S. et al. "Chondroitinase ABC delivered to the site of a spinal cord injury upregulates GAP-43 expression in dorsal root ganglion neurons" <i>Society for Neuroscience Abstracts</i> , 2000, 26(1-2):Abstract no. 324.3 from 30 th Annual Meeting of the Society of Neuroscience, presented November, 2000; mailed to subscribers September, 2000.	
	R3	BERTOLOTTO, A. et al. "Immunohistochemical Localization of Chondroitin Sulfate in Normal and Pathological Human Muscle" <i>J Neurol Sci</i> , 1986, 73:233-244.	
	R4	BRADBURY, E.J. et al. "Chondroitinase ABC promotes functional recovery after spinal cord injury" <i>Nature</i> , April 2002, 416(6881):636-640.	
	R5	BRADBURY, E.J. et al. "Chondroitinase ABC promotes functional recovery after spinal cord injury" <i>Nature</i> , 2002, 416:636-640.	
	R6	BRADBURY, E.J. et al. "Chondroitinase ABC Delivered to the Site of a Spinal Cord Injury Upregulates GAP-43 Expression in Dorsal Root Ganglion Neurons" <i>Soc. Neurosci Abstr</i> , November 2000, abstract presented at the 30 th Annual Meeting of the Society of Neuroscience.	
	R7	BRAUNEWELL, K-H. et al. "Functional Involvement of Sciatic Nerve-derived Versican- and Decorin-like Molecules and other Chondroitin Sulphate Proteoglycans in ECM-mediated Cell Adhesion and Neurite Outgrowth" <i>Euro. J. Neurosci.</i> , 1995, 7:805-814.	
	R8	BRAUNEWELL, K-H. et al. "Up-regulation of a Chondroitin Sulphate Eptiote during Regeneration of Mouse Sciatic Nerve: Evidence that the Immunoreactive Molecules are Related to the Chondroitin Sulphate Proteoglycans Decorin and Versican" <i>Eur J Neurosci</i> , 1995, 7:792-804.	
	R9	BROWN, M.C. et al. "Further Studies on Motor and Sensory Nerve Regeneration in Mice With Delayed Wallerian Degeneration" <i>Eur J Neurosci</i> , 1994, 6:420-428.	
	R10	DANIELSEN, N. et al. "Predegeneration enhances regeneration into acellular nerve grafts" <i>Brain Res</i> , 1995, 681:105-108.	
	R11	DANIELSEN, N. et al. "Pre-degenerated nerve grafts enhance regeneration by shortening the initial delay period" <i>Brain Res</i> , 1994, 666:250-254.	
	R12	EVANS, P.J. et al. "Regeneration Across Cold Preserved Peripheral Nerve Allografts" <i>Microsurgery</i> , 1999, 19:115-127.	
	R13	EVANS, P.J. et al. "The Peripheral Nerve Allograft: A Comprehensive Review of Regeneration and Neuroimmunology" <i>Prog Neurobiol</i> , 1994, 43:187-233.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	4	of	7	Application Number	10/812,776
				Filing Date	March 29, 2004
				First Named Inventor	David F. Muir
				Group Art Unit	3731
				Examiner Name	
				Attorney Docket Number	UF-336XC3D1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	R14	EVANS, P.J. et al. "Cold Preserved Nerve Allografts: Changes in Basement Membrane, Viability, Immunogenicity, and Regeneration" <i>Muscle Nerve</i> , November 1998, 21:1507-1522.			
	R15	FAWCETT, J.W. and R.J. KEYNES "Peripheral Nerve Regeneration" <i>Annu Rev Neurosci</i> , 1990, 13:43-60.			
	R16	FERGUSON, T.A. and D. Muir "MMP-2 and MMP-9 Increase the Neurite-Promoting Potential of Schwann Cell Basal Laminae and Are Upregulated in Degenerated Nerve" <i>Mol Cell Neurosci</i> , 2000 16:157-167.			
	R17	FU, S.Y. and T. Gordon "The Cellular and Molecular Basis of Peripheral Nerve Regeneration" <i>Mol Neurobiol</i> , 1997, 14(1):67-116.			
	R18	GIANNINI, C. and P. DYCK "The Fate of Schwann Cell Basement Membranes in Permanently Transected Nerves" <i>J Neuropathol Exp Neurol</i> , 1990, 49(6):550-563.			
	R19	GORDON, L. et al. "Predegenerated nerve autografts as compared with fresh nerve autografts in freshly cut and precut motor nerve defects in the rat" <i>J Hand Surg [Am]</i> , January 1979, 4(1):42-47.			
	R20	GULATI, A.K. "Evaluation of acellular and cellular nerve grafts in repair of rat peripheral nerve" <i>J Neurosurg</i> , January 1988, 68:117-123.			
	R21	HASAN, N. et al. "The influence of predegenerated nerve grafts on axonal regeneration from prelesioned peripheral nerves" <i>J Anat</i> , 1996, 189:293-302.			
	R22	IDE, C. et al. "Schwann Cell Basal Lamina and Nerve Regeneration" <i>Brain Res</i> , 1983, 288:61-75.			
	R23	JONES, L.L. et al. "Neurotrophic factors, cellular bridges and gene therapy for spinal cord injury" <i>J. Physiology</i> , 2001, 533.1:83-89.			
	R24	KHERIF, S. et al. "Matrix metalloproteinases MMP-2 and MMP-9 in denervated muscle and injured nerve" <i>Neuropathol Appl Neurobiol</i> , 1998, 24:309-319.			
	R25	KREKOSKI, C.A. et al. "Metalloproteinase-Dependent Predegeneration <i>In Vitro</i> Enhances Axonal Regeneration within Acellular Peripheral Nerve Grafts" <i>J. Neuroscience</i> , December 2002, 22(23):10408-10415.			
	R26	KREKOSKI, C.A. et al. "Axonal Regeneration into Acellular Nerve Grafts Is Enhanced by Degradation of Chondroitin Sulfate Proteoglycan" <i>The Journal of Neuroscience</i> , August 15, 2001, 21(16):6206-6213.			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	5	of	7	Application Number	10/812,776
				Filing Date	March 29, 2004
				First Named Inventor	David F. Muir
				Group Art Unit	3731
				Examiner Name	
				Attorney Docket Number	UF-336XC3D1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	R27	LA FLEUR, M. et al. "Basement Membrane and Repair of Injury to Peripheral Nerve: Defining a Potential Role for Macrophages, Matrix Metalloproteinases, and Tissue Inhibitor of Metalloproteinases-1" <i>J. Exp. Med.</i> , December 1996, 184:2311-2326.			T ²
	R28	LANGLEY, J.N. and H.K. ANDERSON "The Union of Different Kinds of Nerve Fibres" <i>J Physiol.</i> , 1904, 31:365-391.			
	R29	LASSNER, F. et al. "Preservation of Peripheral Nerve Grafts: A Comparison of Normal Saline, HTK Organ Preservation Solution, and DMEM Schwann Cell Culture Medium" <i>J Reconstr Microsurg.</i> , 1995, 11:447-453.			
	R30	LEMONS, M.L. et al. "Chondroitin Sulfate Proteoglycan Immunoreactivity Increases Following Spinal Cord Injury and Transplantation" <i>Exper. Neuro.</i> , 1999, 160:51-65.			
	R31	LEVI, A. et al. "Cold Storage of Peripheral Nerves: An In Vitro Assay of Cell Viability and Function" <i>Glia</i> , 1994, 10:121-131.			
	R32	MCKEON, R.J. et al. "Injury-Induced Proteoglycans Inhibit the Potential for Laminin-Mediated Axon Growth on Astrocytic Scars" <i>Exp. Neuro.</i> , 1995, 136:32-43.			
	R33	MCKEON, R.J. et al. "Reduction of Neurite Outgrowth in a Model of Glial Scarring following CNS Injury is Correlated with the Expression of Inhibitory Molecules on Reactive Astrocytes" <i>J. Neurosci.</i> , 1991, 11(11):3398-3411.			
	R34	MOON, L. et al. "Regeneration of CNS axons back to their target following treatment of adult rat brain with chondroitinase ABC" <i>Nature Neuroscience</i> , May 2001, 4(5):465-466.			
	R35	MUIR, D.F. "Enzymatic De-Inhibition of Axonal Regeneration", Abstract, Grant No. 1R01NS037901-01A1, Computer Retrieval of Information on Scientific Projects (CRISP) database, http://crisp.cit.nih.gov/ , maintained by the Office of Extramural Research at the National Institutes of Health (NIH), April 2, 2001.			
	R36	MUIR, D. et al. "Schwannoma Cell-derived Inhibitor of the Neurite-promoting activity of Laminin" <i>J. Cell Biol.</i> , November 1989, 109:2353-2362.			
	R37	NADIM, W. et al. "The role of Schwann cells and basal lamina tubes in the regeneration of axons through long lengths of freeze-killed nerve grafts" <i>Neuropathol Appl Neurobiol</i> , 1990, 16:411-421.			
	R38	OCHI, M. et al. "Nerve Regeneration in Predegenerated Basal Lamina Graft: The Effect of Duration of Predegeneration on Axonal Extension" <i>Exp Neurol</i> , 1994, 128:216-225.			
	R39	OLMARKER, K. et al. "Chondroitinase ABC (Pharmaceutical Grade) for Chemonucleolysis" <i>Spine</i> , 1996, 21:1952-1956.			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	6	of	7	Application Number	10/812,776
				Filing Date	March 29, 2004
				First Named Inventor	David F. Muir
				Group Art Unit	3731
				Examiner Name	
				Attorney Docket Number	UF-336XC3D1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	R40	SALONEN, V. et al. "Laminin in traumatized peripheral nerve: basement membrane changes during degeneration and regeneration" <i>J Neurocytol</i> , 1987, 16:713-720.			
	R41	SHUBAYEV, V.I. and R.R. MYERS "Upregulation and interaction of TNF α and gelatinases A and B in painful peripheral nerve injury" <i>Brain Res</i> , 2000, 855:83-89.			
	R42	SIEBERT, H. et al. "Matrix Metalloproteinase Expression and Inhibition After Sciatic Nerve Axotomy" <i>J Neuropathol Exp Neurol</i> , January 2001, 60(1):85-93.			
	R43	SMITH-THOMAS, L.C. et al. "Increased axon regeneration in astrocytes grown in the presence of proteoglycan synthesis inhibitors" <i>J. Cell Sci.</i> , 1995, 108:1307-1315.			
	R44	SMITH-THOMAS, L.C. et al. "An inhibitor of neurite outgrowth produced by astrocytes" <i>J. Cell Sci.</i> , 1994, 107:1687-1695.			
	R45	STOLL, G. and H.W. MÜLLER "Nerve Injury, Axonal Degeneration and Neural Regeneration: Basic Insights" <i>Brain Pathology</i> , 1999, 9:313-325.			
	R46	STRASBERG, S.R. et al. "Peripheral Nerve Allograft Preservation Improves Regeneration and Decreases Systemic Cyclosporin A Requirements" <i>Experimental Neurology</i> , 1996, 139:306-316.			
	R47	TASKINEN, H.S. and M. RÖYTÄ "The dynamics of macrophage recruitment after nerve transection" <i>Acta Neuropathol (Berl)</i> , 1997, 93:252-259.			
	R48	TKALEC, A.L. et al. "Isolation and Expression in <i>Escherichia coli</i> of cs/A and cs/B, Genes Coding for the Chondroitin Sulfate-Degrading Enzymes Chondroitinase AC and Chondroitinase B, Respectively, from <i>Flavobacterium heparinum</i> " <i>Appl. Environ. Microbiol.</i> , Jan. 2000, 66(1):29-35.			
	R49	WANG, G-Y. et al. "The role of laminin, a component of Schwann cell basal lamina, in rat sciatic nerve regeneration within antiserum-treated nerve grafts" <i>Brain Res</i> , 1992, 570:116-125.			
	R50	YAMADA, T. et al. "Selective localization of gelatinase A, an enzyme degrading β -amyloid protein, in white matter microglia and in Schwann cells" <i>Acta Neuropathol (Berl)</i> , 1995, 89:199-203.			
	R51	YICK, L-W. et al. "Chondroitinase ABC promotes axonal regeneration of Clarke's neurons after spinal cord injury" <i>NeuroReport</i> , 2000, 11(5):1063-1067.			
	R52	ZUO, J. et al. "Degradation of Chondroitin Sulfate Proteoglycan Enhances the Neurite-Promoting Potential of Spinal Cord Tissue" <i>Exp Neurol</i> , 1998, 154:654-662.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/812,776
		Filing Date	March 29, 2004
		First Named Inventor	David F. Muir
		Group Art Unit	3731
		Examiner Name	
Sheet	7	of	7
		Attorney Docket Number	UF-336XC3D1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R53	ZUO, J. et al. "Chondroitin Sulfate Proteoglycan with Neurite-Inhibiting Activity Is Up-regulated following Peripheral Nerve Injury" <i>J Neurobiol</i> , 1998, 34:41-54.	
	R54	ZUO, J. et al. "Neuronal Matrix Metalloproteinase-2 Degrades and Inactivates a Neurite-Inhibiting Chondroitin Sulfate Proteoglycan" <i>The Journal of Neuroscience</i> , July 15, 1998, 18(4):5203-5211.	
	R55	ZUO, J. et al. "Regeneration of Axons after Nerve Transection Repair Is Enhanced by Degradation of Chondroitin Sulfate Proteoglycan" <i>Exp. Neurology</i> , 2002, 176:221-228.	
	R56	New Zealand Examination Report dated May 20, 2004; cited in counterpart New Zealand application no. 531129.	
	R57		
	R58		
	R59		
	R60		
	R61		
	R62		
	R63		
	R64		
	R65		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.